We are live on
!
Find out more
DP
Diadema Partners Portfolio holdings
AUM
$791M
1-Year Est. Return
245.83%
This Fund
S&P 500
This Quarter
Est. Return
+23.31%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$204M
(+35%)
Cap. Flow
+$24.2M
Cap. Flow
% of AUM
3.06%
Top 10 Holdings %
Top 10 Hldgs %
37.34%
Holding
211
New
67
Increased
36
Reduced
24
Closed
63
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$35.2M |
| 2 |
United Therapeutics
UTHR
|
+$14.5M |
| 3 |
ABVX
Abivax
ABVX
|
+$9.93M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$9.38M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$9.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$10.4M |
| 2 |
TERN
Terns Pharmaceuticals
TERN
|
+$9.58M |
| 3 |
TG Therapeutics
TGTX
|
+$8.47M |
| 4 |
Incyte
INCY
|
+$7.74M |
| 5 |
Johnson & Johnson
JNJ
|
+$7.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 66.57% |
| 2 | Healthcare | 33.4% |
| 3 | Consumer Discretionary | 0.02% |
| 4 | Financials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
UroGen Pharma
URGN
$2.16B
| $263K | 0.03% |
7,137
-16,018
| -69% | -$434K |
|
|
127
Amgen
AMGN
$236B
| $215K | 0.03% |
+102,701
| New | +$35.2M |
|
128
Heron Therapeutics
HRTX
$65.3M
| $196K | 0.02% |
+458,723
| New | +$368K |
|
129
Talphera
TLPH
$62.3M
| $158K | 0.02% |
153,563
| – | – |
|
130
Annexon
ANNX
$923M
| $157K | 0.02% |
27,516
-105,400
| -79% | -$583K |
|
131
Monopar Therapeutics
MNPR
$789M
| $151K | 0.02% |
1,630
| – | – |
|
132
Lakeland Industries
LAKE
$118M
| $151K | 0.02% |
+14,108
| New | +$142K |
|
|
UPB
133
Upstream Bio Inc
UPB
$329M
| $132K | 0.02% |
19,093
-2,516
| -12% | -$21.1K |
|
134
MeiraGTx Holdings
MGTX
$1.33B
| $113K | 0.01% |
+8,368
| New | +$83.2K |
|
|
JATT
135
JATT II Acquisition Corp
JATT
$95.2M
| $102K | 0.01% |
+9,021
| New | +$95.9K |
|
|
KLRA
136
Kailera Therapeutics
KLRA
$2.1B
| $79.8K | 0.01% |
+3,621
| New | +$79.6K |
|
137
MannKind Corp
MNKD
$1.31B
| $68.2K | 0.01% |
16,003
-170,600
| -91% | -$554K |
|
138
Entera Bio
ENTX
$519M
| $41.2K | 0.01% |
23,260
| – | – |
|
139
ARS Pharmaceuticals
SPRY
$559M
| $38.9K | ﹤0.01% |
+4,860
| New | +$41.8K |
|
140
Aprea Therapeutics
APRE
$10M
| $36K | ﹤0.01% |
+44,907
| New | +$37.5K |
|
|
TVRD
141
Tvardi Therapeutics
TVRD
$25.5M
| $31.6K | ﹤0.01% |
+16,607
| New | +$52.1K |
|
142
CALL
VistaGen Therapeutics
VTGN
$10.8M
| $13K | ﹤0.01% |
+57,700
| New | +$34.8K |
|
143
NextCure
NXTC
$35.8M
| $12.4K | ﹤0.01% |
+7,742
| New | +$57.2K |
|
|
ATYR
144
PUT
aTyr Pharma
ATYR
$48.8M
| $7.46K | ﹤0.01% |
12,500
| – | – |
|
|
145
CALL
MeiraGTx Holdings
MGTX
$1.33B
| $6.75K | ﹤0.01% |
+500
| New | +$4.97K |
|
|
JBIO
146
PUT
Jade Biosciences
JBIO
$1.27B
| $3.17K | ﹤0.01% |
1,046
| – | – |
|
147
CALL
Erasca
ERAS
$5.66B
| $1.83K | ﹤0.01% |
+100
| New | +$1.43K |
|
148
CALL
Cue Biopharma
CUE
$199M
| $6 | ﹤0.01% |
+6
| New | +$136 |
|
149
AbbVie
ABBV
$453B
| – | – |
-24,058
| Closed | -$5.23M |
|
150
Alkermes
ALKS
$7.73B
| – | – |
-50,000
| Closed | -$1.77M |
|
Similar funds
KAS
FSAG
KAS
BSSFA
GUB
EA
BBES
GEA
Diadema Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Diadema Partners held 211 positions worth $791M, up 35% from $588M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Diadema Partners deployed $24.2M of net new capital in Q2 2026, opening 67 new positions and adding to 36 existing holdings. Its largest new stake was Amgen: 102,701 shares worth $215K.
By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 62% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $7.4M trimmed.
- Diadema Partners's largest Q2 2026 buy was Amgen: 102,701 shares worth $215K.
- Diadema Partners added most to United Therapeutics in Q2 2026, an estimated $14.5M increase.
- Diadema Partners's biggest Q2 2026 reduction was Johnson & Johnson, cutting an estimated $7.4M.
- Diadema Partners fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $10.4M.
- Diadema Partners's ten largest holdings make up 37% of its $791M portfolio in Q2 2026.
- Diadema Partners opened 67 new positions and closed 63 in Q2 2026.
- Diadema Partners's portfolio value rose 35% quarter-over-quarter to $791M.
Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.